Literature and Online Material

Introduction to ARIA

ESNR-EAN Joint Webinar – Amyloid related imaging abnormalities (ARIA): from trial to clinical practice

ARIA Reporting Templates

Clinical reporting of ARIA should follow a structured report. Here are template reports for baseline scan and monitoring scans, co-developed with the ESNR and the EAN:

Recommended Literature

Considerations for patients with preexisting cerebrovascular disease
Greenberg, S. M., Aparicio, H. J., Furie, K. L., Goyal, M. S., Hinman, J. D., Kozberg, M., Leonard, A., & Fisher, M. J. (2025). Vascular Neurology Considerations for Antiamyloid Immunotherapy: A Science Advisory From the American Heart Association. Stroke, 56(1). https://doi.org/10.1161/STR.0000000000000480

“Amyloid-related imaging abnormalities (ARIA): radiological, biological and clinical characteristics” Brain. 2023 Jun 6;146(11):4414–4424. doi: 10.1093/brain/awad188

ASNR resources https://www.asnr.org/education-resources/alzheimers-webinar-series/

“Alzheimer Disease Anti-Amyloid Immunotherapies: Imaging Recommendations and Practice Considerations for Monitoring of Amyloid-Related Imaging Abnormalities” AJNR Am J Neuroradiol. 2025 Jan 8;46(1):24-32. DOI: 10.3174/ajnr.A8469

Comparing ARIA‐E severity scales and effects of treatment management thresholds
Alzheimers Dement 2022;14:e12376. doi: 10.1002/dad2.12376

Appropriate use recommendations

Cummings, J., Apostolova, L., Rabinovici, G. D., Atri, A., Aisen, P., Greenberg, S., Hendrix, S., Selkoe, D., Weiner, M., Petersen, R. C., & Salloway, S. (2023). Lecanemab: Appropriate Use Recommendations. The Journal of Prevention of Alzheimer’s Disease, 10(3), 362–377. link

Rabinovici, G. D., Selkoe, D. J., Schindler, S. E., Aisen, P., Apostolova, L. G., Atri, A., Greenberg, S. M., Hendrix, S. B., Petersen, R. C., Weiner, M., Salloway, S., & Cummings, J. (2025). Donanemab: Appropriate use recommendations. The Journal of Prevention of Alzheimer’s Disease, 12(5), 100150. link

Park, K. H., Kim, G. H., Kim, C.-H., Koh, S.-H., Moon, S. Y., Park, Y. H., Seo, S. W., Yoon, B., Lim, J.-S., Kim, B. C., Kim, H.-J., Na, H. R., Shim, Y., Yang, Y., Lee, C.-N., Rhee, H. Y., Jung, S., Jeong, J. H., Choi, H., … Choi, S. H. (2024). Lecanemab: Appropriate Use Recommendations by Korean Dementia Association. Dementia and Neurocognitive Disorders, 23(4), 165. link